Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Qian, Jian ^a   Zhou, Hai ^a   Chen, Jiawei ^b   Ding, Qi ^c   Cao, Qiang ^a   Qin, Chao ^a   Shao, Pengfei ^a   Li, Pu ^a   Cai, Hongzhou ^a   Meng, Xiaoxin ^a   Ju, Xiaobing ^a   Wang, Meilin ^a   Zhang, Zhengdong ^a   Li, Jie ^a   Hua, Lixin ^a   Yin, Changjun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SUZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; IGFBP3 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CHINESE; CONTROLLED STUDY; FAMILY HISTORY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IGF I GENE; IGFBP 3 GENE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; DRINKING BEHAVIOR; GENETIC PREDISPOSITION; GENETICS; PROSTATE TUMOR; RISK; SMOKING; STATISTICAL MODEL;

AGE FACTORS; ALCOHOL DRINKING; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SMOKING;

EID: 84896133566     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085609     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29.
2. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90: 162-173. (Pubitemid 34779587)
3. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, et al. (2007) Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57: 190-205. (Pubitemid 47312080)
4. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490. (Pubitemid 39505434)
5. Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, et al. (2009) Gene polymorphisms and prostate cancer: the evidence. BJU Int 104: 1560-1572.
6. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34.
7. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244. (Pubitemid 32275588)
8. Maroni PD, Koul S, Meacham RB, Koul HK (2004) Mitogen Activated Protein kinase signal transduction pathways in the prostate. Cell Commun Signal 2: 5.
9. McIntosh J, Dennison G, Holly JM, Jarrett C, Frankow A, et al. (2010) IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J Biol Chem 285: 38788-38800.
10. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. (Pubitemid 37328931)
11. Pollak M (2000) Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 10 Suppl A: S6-7.
12. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854. (Pubitemid 35454590)
13. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566. (Pubitemid 28067285)
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396. (Pubitemid 28209997)
15. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625. (Pubitemid 29194048)
16. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, et al. (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156. (Pubitemid 29042692)
17. Zhang M, Hu Z, Huang J, Shu Y, Dai J, et al. (2010) A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 16: 1236-1244.
18. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, et al. (2007) Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 104: 309-319. (Pubitemid 47231277)
19. Qian B, Zheng H, Yu H, Chen K (2011) Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Res Treat 130: 217-226.
20. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489.
21. Peehl DM, Cohen P, Rosenfeld RG (1996) The role of insulin-like growth factors in prostate biology. J Androl 17: 2-4. (Pubitemid 26090524)
22. Rosen CJ (1999) Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clin Chem 45: 1384-1390.
23. Qu BH, Karas M, Koval A, LeRoith D (1999) Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation. J Biol Chem 274: 31179-31184.
24. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47. (Pubitemid 46220849)
25. Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, et al. (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98: 123-134. (Pubitemid 43159967)
26. Chen W, Wang S, Tian T, Bai J, Hu Z, et al. (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17: 1668-1675.
27. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, et al. (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22: 3104-3112. (Pubitemid 41103723)
28. Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE (2009) Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis 30: 2042-2046.
29. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, et al. (2006) IGF1 Gene Polymorphism and Risk for Hereditary Nonpolyposis Colorectal Cancer. JNCI Journal of the National Cancer Institute 98: 139-143. (Pubitemid 43159969)
30. Lin J-K, Shen M-Y, Lin T-C, Lan Y-T, Wang H-S, et al. (2010) Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma. The International Journal of Biological Markers: 0-0.
31. McGrath M, Lee IM, Buring J, De Vivo I (2011) Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecologic Oncology 120: 174-178.
32. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, et al. (2010) A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics 19: 3089-3101.
33. Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami H-O, et al. (2009) Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. The Prostate 69: 1281-1291.
34. Darago A, Sapota A, Matych J, Nasiadek M, Skrzypinska-Gawrysiak M, et al. (2011) The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer. Clin Chem Lab Med 49: 1699-1705.
35. Peng L, Tang S, Xie J, Luo T, Dai B (2002) Quantitative analysis of IGF-1 and its application in the diagnosis of prostate cancer. Hua Xi Yi Ke Da Xue Xue Bao 33: 137-139.
36. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, et al. (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98: 2612-2615. (Pubitemid 26415083)
37. Maslov AY, Vijg J (2009) Genome instability, cancer and aging. Biochim Biophys Acta 1790: 963-969.
38. Morimoto LM (2005) Variation in Plasma Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3: Genetic Factors. Cancer Epidemiology Biomarkers & Prevention 14: 1394-1401.